- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01413906
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
May 31, 2013 updated by: Bristol-Myers Squibb
The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 2778577
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment
- Men and woman, 20 years of age and above
Exclusion Criteria:
- Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments
- Inability to swallow oral medication
- Uncontrolled or significant cardiovascular disease
- Inadequate bone marrow function
- Inadequate hepatic function
- Inadequate renal function
- Pancreatitis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: BMS-833923 (XL139)
|
Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Dose Limiting Toxicity (DLT) and observed adverse events
Time Frame: Within the first 28 days of treatment
|
Within the first 28 days of treatment
|
Incidence of Dose Limiting Toxicity (DLT) and observed adverse events
Time Frame: Up to 90 days additional treatment period plus 60 days of follow-up
|
Up to 90 days additional treatment period plus 60 days of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of subjects experienced DLT
Time Frame: Within the first 28 days
|
Within the first 28 days
|
Maximum observed concentration (Cmax) of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Trough observed concentration (Cmin) of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Time of maximum observed concentration (Tmax) of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Effective half-life (T-half,eff) of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Accumulation index (AI) of BMS-833923 (XL139)
Time Frame: Day1 and Day 29
|
Day1 and Day 29
|
Best overall response assessed according to Response evaluation criteria in solid tumors (RECIST) v1.1 criteria
Time Frame: Up to120 days of treatment period
|
Up to120 days of treatment period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
August 4, 2011
First Submitted That Met QC Criteria
August 9, 2011
First Posted (Estimate)
August 10, 2011
Study Record Updates
Last Update Posted (Estimate)
June 3, 2013
Last Update Submitted That Met QC Criteria
May 31, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- CA194-010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on BMS-833923 (XL139)
-
University Health Network, TorontoCompletedBasal Cell Nevus SyndromeCanada
-
Bristol-Myers SquibbExelixisCompletedBasal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)United States, Canada
-
Bristol-Myers SquibbCompletedLeukemiaUnited States, Canada, Finland, Italy, United Kingdom, France, Germany
-
Bristol-Myers SquibbTerminatedLeukemiaFrance, United States, Spain, Poland, Finland, Argentina, Canada, Belgium
-
Bristol-Myers SquibbExelixisCompletedStomach Neoplasms | Esophageal NeoplasmsUnited States, Canada, France, Netherlands
-
Bristol-Myers SquibbExelixisCompletedSmall Cell Lung CarcinomaUnited States, Canada, Australia, France, Ireland
-
Bristol-Myers SquibbExelixisCompletedAdvanced Cancer, Various, NOSUnited States
-
CelgeneRecruitingProstatic NeoplasmsUnited States
-
Bristol-Myers SquibbCompletedHeart FailureUnited States
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...UnknownCoronary Artery EctasiaChina